Glenmede Trust’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.6M Sell
95,969
-35,418
-27% -$1.52M 0.02% 465
2026
Q1
$4.83M Sell
131,387
-29,374
-18% -$1.39M 0.02% 447
2025
Q4
$8.18M Buy
+160,761
New +$8.22M 0.04% 380
2025
Q1
$11.5M Sell
165,835
-131,757
-44% -$10.9M 0.06% 328
2024
Q4
$25.6M Buy
297,592
+2,162
+0.7% +$234K 0.13% 145
2024
Q3
$35.2M Sell
295,430
-5,143
-2% -$686K 0.17% 117
2024
Q2
$42.9M Buy
300,573
+14,253
+5% +$1.89M 0.22% 96
2024
Q1
$36.8M Buy
286,320
+28,256
+11% +$3.36M 0.18% 117
2023
Q4
$26.7M Buy
258,064
+665
+0.3% +$65.8K 0.14% 155
2023
Q3
$23.4M Buy
257,399
+47,005
+22% +$4.14M 0.13% 164
2023
Q2
$16.7M Hold
210,394
0.1% 229
2023
Q1
$16.7M Sell
210,394
-3,178
-1% -$225K 0.1% 228
2022
Q4
$14.5M Sell
213,572
-2,556
-1% -$150K 0.08% 264
2022
Q3
$10.8M Sell
216,128
-5,428
-2% -$291K 0.07% 303
2022
Q2
$12.3M Sell
221,556
-60,616
-21% -$3.36M 0.07% 309
2022
Q1
$15.7M Buy
282,172
+22,068
+8% +$1.13M 0.08% 304
2021
Q4
$14.6M Sell
260,104
-7,962
-3% -$431K 0.07% 323
2021
Q3
$12.9M Sell
268,066
-40,640
-13% -$1.96M 0.07% 319
2021
Q2
$12.9M Sell
308,706
-10,102
-3% -$392K 0.07% 314
2021
Q1
$10.7M Sell
318,808
-32,410
-9% -$1.15M 0.06% 319
2020
Q4
$12.3M Buy
351,218
+4,208
+1% +$145K 0.07% 299
2020
Q3
$12M Sell
347,010
-2,086
-0.6% -$69.5K 0.07% 287
2020
Q2
$11.4M Sell
349,096
-16,252
-4% -$519K 0.07% 289
2020
Q1
$10.6M Hold
365,348
0.05% 361
2019
Q4
$10.6M Buy
365,348
+1,212
+0.3% +$33.6K 0.05% 361
2019
Q3
$9.41M Buy
364,136
+4,134
+1% +$105K 0.04% 360
2019
Q2
$9.19M Buy
360,002
+1,906
+0.5% +$47.1K 0.04% 383
2019
Q1
$9.36M Buy
358,096
+112
+0% +$2.75K 0.04% 382
2018
Q4
$8.24M Sell
357,984
-153,316
-30% -$3.41M 0.04% 366
2018
Q3
$12.1M Buy
511,300
+148,774
+41% +$3.63M 0.05% 362
2018
Q2
$8.36M Sell
362,526
-210,814
-37% -$5.01M 0.04% 385
2018
Q1
$15.4M Hold
573,340
0.06% 332
2017
Q4
$15.4M Sell
573,340
-179,248
-24% -$4.56M 0.06% 332
2017
Q3
$18.1M Sell
752,588
-15,206
-2% -$344K 0.08% 307
2017
Q2
$13.2M Hold
767,794
0.06% 338
2017
Q1
$13.2M Buy
767,794
+201,740
+36% +$3.51M 0.06% 338
2016
Q4
$10.1M Sell
566,054
-48,810
-8% -$885K 0.06% 359
2016
Q3
$12.8M Sell
614,864
-94,702
-13% -$2.35M 0.07% 341
2016
Q2
$19.1M Sell
709,566
-5,162
-0.7% -$142K 0.12% 277
2016
Q1
$19.4M Sell
714,728
-149,782
-17% -$4.01M 0.13% 264
2015
Q4
$25.1M Buy
864,510
+62,616
+8% +$1.73M 0.17% 191
2015
Q3
$21.7M Buy
801,894
+45,182
+6% +$1.28M 0.16% 216
2015
Q2
$20.7M Sell
756,712
-15,226
-2% -$428K 0.15% 229
2015
Q1
$20.6M Buy
771,938
+128,982
+20% +$2.97M 0.15% 225
2014
Q4
$13.6M Sell
642,956
-19,982
-3% -$446K 0.11% 289
2014
Q3
$15.8M Sell
662,938
-39,952
-6% -$919K 0.14% 231
2014
Q2
$16.2M Sell
702,890
-34,370
-5% -$759K 0.15% 215
2014
Q1
$16.8M Buy
737,260
+8,050
+1% +$172K 0.16% 176
2013
Q4
$13.5M Sell
729,210
-18,080
-2% -$315K 0.14% 199
2013
Q3
$12.6M Sell
747,290
-28,890
-4% -$486K 0.15% 167
2013
Q2
$12M Buy
+776,180
New +$12.9M 0.15% 142

Other funds holding NVO

Glenmede Trust's NVO Position: Q2 2026 in Review

Glenmede Trust reduced its Novo Nordisk (NVO) stake by 27% in Q2 2026, selling an estimated $1.52M and leaving 95,969 shares worth $4.6M. The position accounts for 0.02% of the portfolio, ranked #465.

Glenmede Trust first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. The position peaked at $42.9M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Glenmede Trust held 95,969 shares of Novo Nordisk worth $4.6M as of Q2 2026.
  • Glenmede Trust sold 35,418 Novo Nordisk shares in Q2 2026, an estimated $1.52M.
  • Novo Nordisk made up 0.02% of Glenmede Trust's portfolio in Q2 2026, its #465 holding.
  • Glenmede Trust first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
  • Glenmede Trust's Novo Nordisk position peaked at $42.9M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.